SEC Filing Summary: Genesis Biopharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Genesis Biopharma, Inc. (not IOVANCE Biotherapeutics, Inc.) on July 20, 2011, reporting events occurring on July 18, 2011. The company is incorporated in Nevada and is headquartered in Los Angeles, California.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the appointment of David Voyticky to the Company's Board of Directors, effective July 18, 2011.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports the board appointment and includes a press release as an exhibit.
Key Facts for Investor Verification
- Verify the background and qualifications of the newly appointed director, David Voyticky.
- Confirm the company name is Genesis Biopharma, Inc., as the input metadata referenced IOVANCE Biotherapeutics, Inc.
- Note that no financial data or operational updates were included in this specific filing.